ES2734070T3 - Formulaciones de etanercept estabilizadas con iones de magnesio - Google Patents

Formulaciones de etanercept estabilizadas con iones de magnesio Download PDF

Info

Publication number
ES2734070T3
ES2734070T3 ES12842352T ES12842352T ES2734070T3 ES 2734070 T3 ES2734070 T3 ES 2734070T3 ES 12842352 T ES12842352 T ES 12842352T ES 12842352 T ES12842352 T ES 12842352T ES 2734070 T3 ES2734070 T3 ES 2734070T3
Authority
ES
Spain
Prior art keywords
etanercept
composition
weight
less
peak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12842352T
Other languages
English (en)
Spanish (es)
Inventor
Mark Manning
Brian Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coherus Oncology Inc
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Application granted granted Critical
Publication of ES2734070T3 publication Critical patent/ES2734070T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
ES12842352T 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con iones de magnesio Active ES2734070T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060739 WO2013059406A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions

Publications (1)

Publication Number Publication Date
ES2734070T3 true ES2734070T3 (es) 2019-12-04

Family

ID=48136153

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12842352T Active ES2734070T3 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con iones de magnesio

Country Status (28)

Country Link
US (21) US10293049B2 (enExample)
EP (6) EP2768854A4 (enExample)
JP (6) JP6113176B2 (enExample)
KR (7) KR20140091706A (enExample)
CN (6) CN104010658A (enExample)
AR (6) AR088381A1 (enExample)
AU (6) AU2012326082B2 (enExample)
BR (6) BR112014009131A8 (enExample)
CA (6) CA2851635A1 (enExample)
CY (1) CY1121843T1 (enExample)
DK (1) DK2768525T3 (enExample)
EA (6) EA026410B1 (enExample)
ES (1) ES2734070T3 (enExample)
HK (3) HK1200722A1 (enExample)
HR (1) HRP20191215T1 (enExample)
HU (1) HUE045624T2 (enExample)
IL (6) IL231827A0 (enExample)
IN (3) IN2014CN02591A (enExample)
LT (1) LT2768525T (enExample)
MX (7) MX2014004733A (enExample)
PL (1) PL2768525T3 (enExample)
PT (1) PT2768525T (enExample)
RS (1) RS59179B1 (enExample)
SG (6) SG11201401567YA (enExample)
SI (1) SI2768525T1 (enExample)
SM (1) SMT201900422T1 (enExample)
TW (6) TW201325607A (enExample)
WO (6) WO2013059405A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101217979A (zh) 2005-06-14 2008-07-09 安姆根有限公司 自缓冲蛋白制剂
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
AR088381A1 (es) * 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con meglumina
CA2878508A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
SG11201501460RA (en) * 2012-09-11 2015-04-29 Coherus Biosciences Inc Correctly folded etanercept in high purity and excellent yield
SG11201508900UA (en) * 2013-05-02 2015-11-27 Mabxience S A Alternative formulations for tnfr: fc fusion polypeptides
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
KR102109053B1 (ko) * 2013-10-24 2020-05-13 아스트라제네카 아베 안정한 수성 항체 제제
US9700595B2 (en) 2013-11-29 2017-07-11 Ares Trading Sa Liquid formulation of a fusion protein comprising TNFR and Fc region
IS3008B (is) 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
WO2021108427A1 (en) * 2019-11-26 2021-06-03 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US20180200325A1 (en) 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
AU2015371381A1 (en) * 2014-12-22 2017-07-20 Ares Trading S.A. Liquid pharmaceutical composition
EP3236942A1 (en) * 2014-12-23 2017-11-01 Drug Discovery Laboratory AS Protein compositions and use thereof
IL253218B (en) * 2014-12-31 2022-08-01 Lg Chemical Ltd A method for preparing a tnfr–fc fusion protein containing a targeted content of unpurified components
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
WO2017179683A1 (ja) * 2016-04-15 2017-10-19 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
EA201990998A1 (ru) * 2016-10-21 2019-11-29 Фармацевтические составы и способы их получения
US11236146B2 (en) 2016-10-28 2022-02-01 Celltrion Inc. Stable pharmaceutical formulation
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
WO2019105450A1 (zh) * 2017-11-30 2019-06-06 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
JP7692699B2 (ja) * 2017-12-22 2025-06-16 サムスン バイオエピス カンパニー リミテッド Ｖｅｇｆアンタゴニストを含む液体組成物
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
WO2022175663A1 (en) 2021-02-17 2022-08-25 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CN1406132A (zh) 2000-02-10 2003-03-26 惠氏公司 处理或抑制细胞损伤或细胞死亡的方法
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
WO2003102013A2 (en) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Methods and compositions for production of recombinant peptides
MXPA04008215A (es) * 2002-02-27 2004-11-26 Immunex Corp Formulacion polipeptidica.
ATE394123T1 (de) 2003-02-28 2008-05-15 Ares Trading Sa Flüssige formulierungen des tumornekrosefraktor- bindungsproteins tbp-1
EP1607103A1 (en) 2003-03-20 2005-12-21 Eisai Co., Ltd. Concomitant drug as therapeutic agent for inflammatory bowel disease
SG145712A1 (en) 2003-08-01 2008-09-29 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
CN103145715B (zh) 2003-10-14 2016-08-03 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
ES2456015T3 (es) 2004-03-05 2014-04-21 Dsm Ip Assets B.V. Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
CN101217979A (zh) * 2005-06-14 2008-07-09 安姆根有限公司 自缓冲蛋白制剂
SG153832A1 (en) * 2005-12-20 2009-07-29 Bristol Myers Squibb Co Stable protein formulations
CA2634131C (en) 2005-12-21 2014-02-11 Wyeth Protein formulations with reduced viscosity and uses thereof
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
WO2007107340A2 (en) 2006-03-21 2007-09-27 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
CN101627117B (zh) * 2006-08-01 2013-10-30 奇尼塔二有限责任公司 医药制造方法
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
US20080213282A1 (en) 2006-12-21 2008-09-04 Jaby Jacob Formulations
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
EP2170390B1 (en) * 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
JP5840364B2 (ja) 2007-11-30 2016-01-06 アッヴィ バイオテクノロジー リミテッド タンパク質製剤及びその製造方法
CA2711984A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
WO2009111347A1 (en) 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) * 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
DK2563904T3 (en) 2010-04-26 2015-04-07 Novartis Ag Improved cell culture medium
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
US20130150554A1 (en) 2010-08-20 2013-06-13 Wyeth Llc Cell culture of growth factor-free adapted cells
AU2011296702A1 (en) 2010-08-31 2013-03-21 Friesland Brands B.V. Culture medium for eukaryotic cells
KR20130142128A (ko) 2010-10-11 2013-12-27 애브비 인코포레이티드 단백질의 정제 방법
US9453067B2 (en) * 2011-04-20 2016-09-27 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
JP2014518275A (ja) 2011-06-29 2014-07-28 インサイト・ビジョン・インコーポレイテッド 再発性マイボーム腺障害の処置方法およびそれによる再発頻度の減少方法
KR20230114317A (ko) 2011-07-01 2023-08-01 암젠 인크 포유동물 세포 배양
CN103930124B (zh) * 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
AU2012282960A1 (en) 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
JP6223338B2 (ja) 2011-08-17 2017-11-01 アレス トレーディング ソシエテ アノニム 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法
AR088381A1 (es) * 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con meglumina
SG11201501460RA (en) 2012-09-11 2015-04-29 Coherus Biosciences Inc Correctly folded etanercept in high purity and excellent yield

Also Published As

Publication number Publication date
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
IN2014CN02592A (enExample) 2015-09-04
US20190298837A1 (en) 2019-10-03
AR088380A1 (es) 2014-05-28
US20130101584A1 (en) 2013-04-25
AU2012326171B2 (en) 2017-03-09
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (enExample) 2015-06-26
JP2014530256A (ja) 2014-11-17
JP2014530254A (ja) 2014-11-17
IN2014CN02527A (enExample) 2015-06-26
WO2013059406A1 (en) 2013-04-25
CN104010658A (zh) 2014-08-27
CN104011073A (zh) 2014-08-27
US20190314499A1 (en) 2019-10-17
US11129876B2 (en) 2021-09-28
KR20200008021A (ko) 2020-01-22
JP2014530255A (ja) 2014-11-17
KR20140079491A (ko) 2014-06-26
US10376588B2 (en) 2019-08-13
TWI595883B (zh) 2017-08-21
US20190290766A1 (en) 2019-09-26
EA201490804A1 (ru) 2014-09-30
BR112014009146A2 (pt) 2017-06-13
BR112014009073A2 (pt) 2017-05-09
SG11201401517VA (en) 2014-09-26
DK2768525T3 (da) 2019-07-22
EP2768535A1 (en) 2014-08-27
US20200405865A1 (en) 2020-12-31
KR20140097184A (ko) 2014-08-06
SI2768525T1 (sl) 2019-10-30
SMT201900422T1 (it) 2019-09-09
JP6220788B2 (ja) 2017-10-25
US20190290767A1 (en) 2019-09-26
SG11201401567YA (en) 2014-07-30
CA2851628A1 (en) 2013-04-25
MX367054B (es) 2019-08-02
KR20140091706A (ko) 2014-07-22
US20160317667A1 (en) 2016-11-03
RS59179B1 (sr) 2019-10-31
TW201325608A (zh) 2013-07-01
HK1200851A1 (en) 2015-08-14
US11135267B2 (en) 2021-10-05
BR112014009087A2 (pt) 2017-04-18
US10980884B2 (en) 2021-04-20
HK1200722A1 (en) 2015-08-14
US20190290765A1 (en) 2019-09-26
WO2013059412A1 (en) 2013-04-25
BR112014009131A2 (pt) 2017-06-13
SG11201401576WA (en) 2014-10-30
EA201490802A1 (ru) 2014-08-29
US20160199489A1 (en) 2016-07-14
BR112014009131A8 (pt) 2017-06-20
SG11201401519RA (en) 2014-07-30
MX2014004734A (es) 2015-05-15
MX2014004725A (es) 2015-02-05
AU2012326084B2 (en) 2016-12-15
WO2013059407A1 (en) 2013-04-25
MX2014004728A (es) 2015-05-15
MX2014004726A (es) 2015-05-15
US20130108633A1 (en) 2013-05-02
CA2851642A1 (en) 2013-04-25
MX2014004733A (es) 2015-05-15
PL2768525T3 (pl) 2019-10-31
CN103998061A (zh) 2014-08-20
KR20140091705A (ko) 2014-07-22
US20130101640A1 (en) 2013-04-25
US9302002B2 (en) 2016-04-05
EP2768854A1 (en) 2014-08-27
HUE045624T2 (hu) 2020-01-28
TW201325607A (zh) 2013-07-01
JP2014530864A (ja) 2014-11-20
WO2013059408A1 (en) 2013-04-25
TW201325610A (zh) 2013-07-01
EA027325B1 (ru) 2017-07-31
TW201325611A (zh) 2013-07-01
TW201325609A (zh) 2013-07-01
AU2012326082B2 (en) 2016-12-15
US20190314498A1 (en) 2019-10-17
CA2851639C (en) 2020-12-29
IL231826A0 (en) 2014-05-28
SG11201401562RA (en) 2014-09-26
EA201490801A1 (ru) 2014-09-30
US9801942B2 (en) 2017-10-31
CN103998060B (zh) 2016-12-21
JP6110393B2 (ja) 2017-04-05
IL231825A0 (en) 2014-05-28
JP6199298B2 (ja) 2017-09-20
KR102068462B1 (ko) 2020-01-22
KR20140083037A (ko) 2014-07-03
US9770510B2 (en) 2017-09-26
AR088460A1 (es) 2014-06-11
CN104010657A (zh) 2014-08-27
EP2768533A1 (en) 2014-08-27
AR088381A1 (es) 2014-05-28
EA201490803A1 (ru) 2014-09-30
US20190290768A1 (en) 2019-09-26
KR20140091707A (ko) 2014-07-22
AU2012326084A1 (en) 2014-04-17
KR102163150B1 (ko) 2020-10-08
TWI619504B (zh) 2018-04-01
AU2012326171A1 (en) 2014-04-24
US10772963B2 (en) 2020-09-15
EP2768532A4 (en) 2015-03-11
BR112014009146A8 (pt) 2017-06-20
CY1121843T1 (el) 2020-07-31
IL231824A0 (en) 2014-05-28
EP2768531A1 (en) 2014-08-27
EA026410B1 (ru) 2017-04-28
AU2012326168B2 (en) 2016-12-15
US10213508B2 (en) 2019-02-26
EP2768535A4 (en) 2015-03-11
JP2014530863A (ja) 2014-11-20
HK1200721A1 (en) 2015-08-14
HK1200720A1 (en) 2015-08-14
EP2768525B1 (en) 2019-06-19
JP6220789B2 (ja) 2017-10-25
CA2851639A1 (en) 2013-04-25
US10980885B2 (en) 2021-04-20
AU2012326082A1 (en) 2014-04-24
US20190314500A1 (en) 2019-10-17
CN104010654B (zh) 2017-10-27
CA2851635A1 (en) 2013-04-25
AU2012326170A1 (en) 2014-04-24
TWI644681B (zh) 2018-12-21
US20130108632A1 (en) 2013-05-02
AR088382A1 (es) 2014-05-28
PT2768525T (pt) 2019-07-17
US20180193463A1 (en) 2018-07-12
LT2768525T (lt) 2019-09-25
HRP20191215T1 (hr) 2019-10-04
EP2768532A1 (en) 2014-08-27
JP2014530862A (ja) 2014-11-20
BR112014009022A2 (pt) 2017-05-02
CN103998060A (zh) 2014-08-20
AU2012326170B2 (en) 2016-12-22
EA025663B1 (ru) 2017-01-30
HK1200718A1 (en) 2015-08-14
BR112014009031A2 (pt) 2017-05-09
AU2012326080A1 (en) 2014-04-24
US10888619B2 (en) 2021-01-12
EA025267B1 (ru) 2016-12-30
US20180125982A1 (en) 2018-05-10
IL231829A0 (en) 2014-05-28
IL231828A0 (en) 2014-05-28
JP6104922B2 (ja) 2017-03-29
AU2012326168A1 (en) 2014-04-24
CN104010654A (zh) 2014-08-27
EA028520B1 (ru) 2017-11-30
EP2768525A1 (en) 2014-08-27
EP2768531A4 (en) 2015-03-11
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
MX2014004732A (es) 2015-05-15
US9943601B2 (en) 2018-04-17
EA201490817A1 (ru) 2014-09-30
EP2768525A4 (en) 2015-07-15
CA2851646A1 (en) 2013-04-25
MX2019009176A (es) 2019-10-07
AR088383A1 (es) 2014-05-28
SG11201401563SA (en) 2014-09-26
EP2768854A4 (en) 2015-03-11
IL231827A0 (en) 2014-05-28
EA201490815A1 (ru) 2014-09-30
US20190216930A1 (en) 2019-07-18
EP2768533A4 (en) 2015-03-11
US10987405B2 (en) 2021-04-27
CN104011073B (zh) 2017-08-25
AU2012326080B2 (en) 2017-02-16
TW201325606A (zh) 2013-07-01
US20190184017A1 (en) 2019-06-20
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
AR088379A1 (es) 2014-05-28
JP6113176B2 (ja) 2017-04-12
CA2851651A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
ES2734070T3 (es) Formulaciones de etanercept estabilizadas con iones de magnesio
HK1200851B (en) Etanercept formulations stabilized with amino acids